$1.5 B

ONCE Mkt cap, 04-Dec-2018

$10.7 M

Spark Therapeutics Revenue Q3, 2018
Spark Therapeutics Gross profit (Q3, 2018)10.4 M
Spark Therapeutics Gross profit margin (Q3, 2018), %97%
Spark Therapeutics Net income (Q3, 2018)-47.4 M
Spark Therapeutics EBIT (Q3, 2018)-51.7 M
Spark Therapeutics Cash, 30-Sep-2018161.6 M
Spark Therapeutics EV1.4 B

Spark Therapeutics Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

633.9k22.1m20.2m12.1m

Revenue growth, %

3380%(9%)

R&D expense

16.4m46.0m86.4m135.2m

General and administrative expense

7.9m23.4m48.1m111.1m

Operating expense total

24.2m69.4m145.6m270.6m

EBIT

(24.3m)(47.3m)(125.4m)(258.5m)

EBIT margin, %

(3838%)(214%)(621%)(2143%)

Interest income

192.0k1.7m4.1m

Pre tax profit

(254.4m)

Income tax expense

963.0k

Net Income

(24.3m)(47.1m)(123.7m)(253.5m)

Spark Therapeutics Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

74.6m293.5m58.9m96.7m

Accounts Receivable

244.4k16.9m16.8m

Current Assets

77.4m311.6m314.6m533.2m

PP&E

12.7m17.0m19.8m61.7m

Goodwill

1.2m1.3m

Total Assets

90.4m329.8m373.9m616.8m

Accounts Payable

2.7m9.7m9.9m14.2m

Short-term debt

302.0k312.0k

Current Liabilities

15.9m22.1m30.0m53.7m

Long-term debt

1.2m912.0k

Total Debt

1.5m1.2m

Total Liabilities

43.6m103.2m

Additional Paid-in Capital

54.4m419.8m584.0m1.0b

Retained Earnings

(81.6m)(128.7m)(252.4m)(505.9m)

Total Equity

55.2m290.5m330.3m513.6m

Debt to Equity Ratio

0 x0 x

Debt to Assets Ratio

0 x0 x

Financial Leverage

1.6 x1.1 x1.1 x1.2 x

Spark Therapeutics Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(24.3m)(47.1m)(123.7m)(253.5m)

Depreciation and Amortization

169.8k1.7m3.6m4.9m

Accounts Receivable

(144.4k)(16.7m)(234.8k)8.9m

Accounts Payable

2.3m9.1m10.0m13.0m

Cash From Operating Activities

10.4m(47.5m)(80.4m)(154.5m)

Purchases of PP&E

(11.7m)(4.5m)(8.5m)(9.7m)

Cash From Investing Activities

(11.7m)(4.5m)(285.5m)(207.7m)

Long-term Borrowings

(24.6k)(302.0k)

Cash From Financing Activities

75.9m271.0m131.4m400.3m

Spark Therapeutics Ratios

USDY, 2018

EV/EBIT

-26.4 x

EV/CFO

-48.8 x

Debt/Equity

0.1 x

Debt/Assets

0.1 x

Financial Leverage

1.5 x
Report incorrect company information

Spark Therapeutics Operating Metrics

FY, 2016

Patents and Patent Applications

297
Report incorrect company information

Spark Therapeutics Employee Rating

2.38 votes
Culture & Values
2.1
Work/Life Balance
2.1
Senior Management
2.3
Salary & Benefits
1.9
Career Opportunities
2.0
Source